{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 91,
  "pageCount": 132,
  "prevPage": 90,
  "nextPage": 92,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide includes a vertical navigation bar on the right indicating the therapeutic area 'Oncology' and a page number '91'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/91",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-91",
  "components": [
    {
      "bbox": {
        "h": 1,
        "w": 0.023,
        "x": 0.977,
        "y": 0
      },
      "kind": "other",
      "text": "Oncology, CVRM, R&I, Other, V&I, Rare Disease",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afff4356-61be-4b55-8529-96a3ac459dd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.047,
        "w": 0.127,
        "x": 0.014,
        "y": 0.953
      },
      "kind": "source-note",
      "text": "91 As of 12 November 2024. Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ffde652-cc7d-4b0f-8fdd-f63573aaa78d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.215,
        "w": 0.964,
        "x": 0.036,
        "y": 0.188
      },
      "kind": "table",
      "text": "Trial, Population, Patients, Design, Endpoints, Status. DAISY (NCT05925803), Systemic sclerosis, 306, Arm 1: Saphnelo s.c. Arm 2: placebo s.c. Global trial, Primary endpoint: CRISS-25 at Week 52, FPCD: Q4 2023 Data anticipated: >2025. JASMINE (NCT06455449), Idiopathic inflammatory myopathies, 240, Arm 1: Saphnelo s.c. Arm 2: placebo s.c. Global trial, Primary endpoint: Total Improvement Score ≥ 40 at Week 52, Initiating Data anticipated: >2025.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d1778f3-d610-4ece-b38c-75e27384708d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.165,
        "w": 0.615,
        "x": 0.036,
        "y": 0.045
      },
      "kind": "title",
      "text": "Saphnelo (type I interferon receptor mAb) Sclerosis and other myopathies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "844b5244-3a9c-41c1-a46a-622bb3be9c22",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}